U.S. market Closed. Opens in 1 hour 21 minutes

NTLA | Intellia Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Revenue36.27M52.12M33.05M57.99M43.10M30.43M26.12M16.48M6.04MN/A
Cost of Revenue8.98M7.57M6.89M150.41M108.41M89.11M67.65M31.84M11.17M1.66M
Gross Profit27.30M44.55M26.16M-92.41M-65.31M-58.68M-41.53M-15.36M-5.13M-1.66M
Operating Expenses551.57M510.29M300.90M194.58M149.47M121.30M95.67M48.64M19.45M12.65M
Selling, General & Admin116.50M90.31M71.10M44.17M41.06M32.19M28.02M16.80M8.28M3.57M
Research & Development435.07M419.98M229.81M150.41M108.41M89.11M67.65M31.84M11.17M10.74M
Other Operating ExpensesN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Operating Income-515.29M-458.16M-267.85M-136.58M-106.37M-90.87M-69.56M-32.16M-13.41M-5.23M
Other Expenses / Income34.10M-16.02M-42.00K2.35M6.83M5.53M2.01M525.00KN/A-9.08M
Before Tax Income-481.19M-474.19M-267.89M-134.23M-99.53M-85.34M-67.54M-31.63M-13.41M-14.31M
Income Tax ExpensesN/A16.02M-8.17M-8.66M-6.83M5.53M-2.99M-1.10M-1.01MN/A
Net Income-481.19M-490.21M-259.72M-125.57M-92.70M-85.34M-67.54M-31.63M-12.40M-14.31M
Interest ExpensesN/A8.54MN/AN/AN/AN/AN/AN/AN/AN/A
Basic Shares Outstanding88.77M76.97M70.89M55.99M47.25M43.07M36.01M22.22M17.66M485.88K
Diluted Shares Outstanding88.77M76.97M70.89M55.99M47.25M43.07M36.01M22.22M17.66M485.88K
EBITDA-506.31M-450.59M-260.96M-130.27M-100.78M-86.41M-66.56M-31.05M-13.08M-9.54M
EBITDA Margin-1,395.77%-864.51%-789.52%-224.63%-233.81%-283.91%-254.86%-188.45%-216.43%0.00%
EBIT-481.19M-465.64M-267.89M-134.23M-99.53M-79.82M-70.54M-32.74M-13.41M-14.31M
EBIT Margin-1,326.51%-893.39%-810.49%-231.46%-230.92%-262.26%-270.08%-198.66%-221.86%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙